Long-acting progestin delivery may outpace daily pills in endometriosis care

Endometriosis affects roughly 10 to 15 percent of women of reproductive age worldwide, about 200 million people, a figure projected to reach 220 million by 2050. Global burden estimates show a 10.37 percent rise in incident cases and a 16.36 percent rise in disability-adjusted life-years between 1990 and 2019. Yet despite this mounting toll, diagnosis is often delayed by 7 to 10 years, and a recent international synthesis reports a mean diagnostic delay of approximately 6.8 years, with cross-country variation from 1.5 to 11.4 years. A new narrative comparative review published in Drugs & Therapy Perspectives argues that the real bottleneck in treatment may not be the drugs themselves but the way they are delivered, and that aligning delivery architecture with the chronic nature of the disease could strengthen established progestin therapies without waiting for new molecules.

The review, led by Lokesh Yadav and colleagues, examines first-line progestins across efficacy, safety, tolerability, and persistence, alongside long-acting platforms including intrauterine systems, vaginal rings, subdermal implants, injectables, and emerging depots. The authors synthesized clinical, pharmacokinetic, and adherence evidence within a unified translational framework, identifying formulation-driven gaps that may influence exposure stability and therapeutic durability. Their central argument is that daily oral progestins, designed for short-acting use, are poorly matched to a chronic, relapsing inflammatory disease that requires sustained hormonal suppression over years, not months.

Progestins occupy a distinctive position among available therapies. They suppress ovulation, induce decidualization and atrophy of ectopic implants, and modulate inflammatory and immune pathways implicated in disease persistence. Their availability across oral, injectable, intrauterine, and implantable platforms supports their use as cost-effective, fertility-preserving therapies suitable for prolonged administration. International guidelines from ESHRE, NICE, and ACOG recommend individualized hormonal therapy as first-line management, and progestins remain the backbone of medical management because of these mechanisms. However, clinical response remains heterogeneous, with relapses, breakthrough bleeding, and intolerance driving discontinuation in a substantial proportion of patients.

The comparative overview in the review highlights meaningful differences among agents. Dienogest combines robust pain efficacy with a generally favorable bone-safety profile. The levonorgestrel-releasing intrauterine system minimizes systemic exposure while providing strong local effects. Norethindrone acetate offers potent symptom control but carries androgenic liabilities. Depot medroxyprogesterone acetate is effective but is associated with bone mineral density loss. These differences in bioavailability, half-life, and metabolic or androgenic effects shape pain relief, bone health, and adherence, meaning the choice of agent must balance efficacy, tolerability, and long-term safety.

Real-world data reveal the scale of the persistence problem. One study reported an overall medical treatment discontinuation rate of 53.6 percent, with combined oral contraceptives carrying the highest risk. Among progestins, reported discontinuation rates range from 0 to 37.1 percent, driven by adverse effects, persistent pain, or perceived lack of efficacy. Mood-related adverse effects further contribute to oral contraceptive discontinuation in endometriosis cohorts. These attrition patterns translate directly into symptom recurrence, lesion progression, and increased healthcare utilization, including repeat surgeries. Median satisfaction with progestin therapy is approximately 62 percent, with 27 percent of patients remaining dissatisfied, a disconnect the authors attribute to side effects and daily treatment burden persisting even when clinical improvement occurs.

Continuation differs strikingly by delivery modality. In a maintenance cohort followed for more than five years, 91.5 percent of patients remained on the levonorgestrel intrauterine system compared with 21.9 percent on oral regimens such as combined oral contraceptives or dienogest, with comparable pain control and fewer systemic side effects in the intrauterine group. In the PRE-EMPT trial, long-acting progestogen methods significantly reduced the number of repeat surgical interventions relative to oral contraceptives, with 73 versus 97 interventions and a hazard ratio of 0.67. Translational evidence from contraception reinforces the pattern: the CHOICE Project reported over 86 percent one-year continuation for implants and intrauterine systems, compared with less than 60 percent for daily oral methods. In adolescents, one-year continuation of the levonorgestrel intrauterine device reached 92 percent.

Breakthrough bleeding emerges as a leading cause of early discontinuation. Although not typically medically serious, it materially affects quality of life, and retrospective analyses identify spotting as a primary driver of cessation, particularly among combined oral contraceptive users. Mechanistically, breakthrough bleeding reflects endometrial instability under sustained hormonal exposure and is influenced by dose, delivery modality, interindividual endometrial responsiveness, and exposure fluctuations. In implants, lower systemic etonogestrel levels correlate with more bleeding irregularity, underscoring sensitivity to exposure stability. Daily oral dosing also introduces substantial pharmacokinetic variability, and missed or delayed doses may precipitate a rapid decline in drug concentrations, resulting in inconsistent progesterone receptor engagement and fluctuating symptom control.

The evidence base itself carries limitations the authors emphasize. Most studies evaluating hormonal therapies in endometriosis do not exceed one year, though notable exceptions such as a three-year pragmatic randomized trial inform durability endpoints. Evidence for the levonorgestrel intrauterine device as disease-modifying therapy after surgery shows potential benefits but remains limited and low certainty in systematic reviews. Interpretation is further constrained by heterogeneity in study populations, endpoints, and treatment durations, and by limited endometriosis-specific clinical evidence for several emerging delivery platforms. Progesterone resistance, driven by altered progesterone receptor B:A ratios, epigenetic silencing of receptor B, and progesterone-antagonistic inflammatory cytokines, contributes to incomplete pain control in up to one-third of patients and defines a biological ceiling beyond which improvements in dose, exposure duration, or formulation alone are unlikely to yield additional benefit.

Among long-acting platforms, the levonorgestrel intrauterine system is the most clinically mature, delivering localized hormone exposure with minimal systemic absorption. Updated labeling now supports contraceptive use for up to 8 years, with a declining in vivo release rate of approximately 21 micrograms per day at 24 days, 11 micrograms per day at 5 years, and 7 micrograms per day at 8 years. Subdermal implants, though not formally approved for endometriosis, have shown reductions in pain, improved quality of life, and continuation rates approaching 93 percent at 2 years in clinical studies. Vaginal rings offer tunable release kinetics and user-controlled dosing, with early studies of danazol-loaded rings and anastrozole-delivering systems showing lesion suppression and pain reduction with lower systemic exposure in preclinical and early clinical settings. Injectable levonorgestrel-loaded PLGA microspheres maintained therapeutic concentrations and suppressed cyst growth for up to 6 months in animal models without systemic effects, while biodegradable in situ forming implants could offer a minimally invasive means to sustain progestin exposure over months.

The authors argue that substantial clinical gains can be achieved by improving how established progestins are delivered, offering a faster and lower-risk route to innovation than introducing new hormonal agents. They call for head-to-head randomized trials comparing emerging long-acting platforms with standard oral progestins and intrauterine systems, using primary endpoints that reflect chronic disease management, including durable pain control, lesion stability where assessable, and treatment continuation over multiyear horizons, alongside pharmacokinetic and pharmacodynamic substudies. They also advocate systematic integration of validated patient-reported outcome instruments and regulatory pathways that leverage real-world evidence for postapproval life-cycle management. Whether improved exposure stability translates into meaningful clinical benefit, they conclude, requires confirmation in appropriately designed comparative studies with sufficiently long follow-up to assess sustained pain control, treatment persistence, safety, quality of life, and reproductive outcomes.

Subject of Research: Drug delivery strategies for first-line progestin therapy in endometriosis

Article Title: Rethinking first-line progestin use in endometriosis: a comparative therapeutic review and future-ready drug delivery perspective

Article References: Yadav, L., Banerjee, A., Patel, A., Krishnamurthy, P. T., Nandave, M., & Patel, S. (2026). Rethinking first-line progestin use in endometriosis: a comparative therapeutic review and future-ready drug delivery perspective. Drugs & Therapy Perspectives. https://doi.org/10.1007/s40267-026-01282-5

Image Credits: AI Generated

DOI: 10.1007/s40267-026-01282-5

Keywords: endometriosis, progestins, drug delivery, levonorgestrel intrauterine system, dienogest, vaginal rings, subdermal implants, breakthrough bleeding, progesterone resistance, treatment discontinuation, hormonal therapy, long-acting reversible contraception